Steinmetz JD, Seeher KM, Schiess N, Nichols E, Cao B, Servili C, et al
This dual-action mechanism is why Tirzepatide consistently delivers better weight loss results, as demonstrated in prior clinical trials
There have, however, been anecdotal reports of patients who stop taking one of these medications because their insurance stops covering it or they switch to a new insurance company (say, due to a job change) and can no longer get coverage
For weight management medications, NICE guidance specifies different stopping rulesfor example, Wegovy treatment should be reviewed after 6 months, and Saxenda should be discontinued if less than 5% weight loss is achieved after 12 weeks at the maintenance dose
Taken after the metabolic window closes, it offers minimal benefit, which is why timing and formulation determine outcomes
Just log into your Pharmacists Letter or Pharmacy Technicians Letter account and look for the title of this podcast in the list of available CE courses